Cambiar Investors LLC Sells 135,838 Shares of Waters Co. (NYSE:WAT)

Cambiar Investors LLC trimmed its position in Waters Co. (NYSE:WAT) by 81.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 31,168 shares of the medical instruments supplier’s stock after selling 135,838 shares during the period. Cambiar Investors LLC owned about 0.05% of Waters worth $11,563,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. Principal Financial Group Inc. lifted its stake in shares of Waters by 70.7% in the 3rd quarter. Principal Financial Group Inc. now owns 656,019 shares of the medical instruments supplier’s stock valued at $236,095,000 after purchasing an additional 271,804 shares during the period. Robeco Institutional Asset Management B.V. lifted its stake in shares of Waters by 34.4% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 393,890 shares of the medical instruments supplier’s stock valued at $141,757,000 after purchasing an additional 100,811 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Waters by 37.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 305,661 shares of the medical instruments supplier’s stock valued at $110,005,000 after purchasing an additional 82,865 shares during the period. Applied Finance Capital Management LLC lifted its stake in shares of Waters by 3,627.0% in the 3rd quarter. Applied Finance Capital Management LLC now owns 68,987 shares of the medical instruments supplier’s stock valued at $24,828,000 after purchasing an additional 67,136 shares during the period. Finally, Smith Group Asset Management LLC acquired a new position in shares of Waters in the 4th quarter valued at $22,188,000. 94.01% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on WAT. Scotiabank began coverage on Waters in a research note on Monday, December 23rd. They set a “sector perform” rating and a $430.00 price objective on the stock. Barclays raised Waters from an “underweight” rating to an “equal weight” rating and raised their price objective for the stock from $360.00 to $415.00 in a research note on Monday. TD Cowen raised their price objective on Waters from $363.00 to $410.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Sanford C. Bernstein raised Waters from a “market perform” rating to an “outperform” rating and set a $430.00 price objective on the stock in a research note on Friday, January 10th. Finally, Wells Fargo & Company raised their price objective on Waters from $380.00 to $415.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. Ten investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $388.64.

Waters Price Performance

Shares of NYSE WAT opened at $407.61 on Tuesday. The stock has a market capitalization of $24.20 billion, a price-to-earnings ratio of 38.89, a PEG ratio of 7.37 and a beta of 1.01. The business has a 50-day moving average of $389.98 and a 200-day moving average of $363.11. The company has a debt-to-equity ratio of 1.14, a current ratio of 2.02 and a quick ratio of 1.38. Waters Co. has a fifty-two week low of $279.24 and a fifty-two week high of $423.56.

About Waters

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.